E. Ohman J:or Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

E. Ohman J:or Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-116,600	Closed	-$19.9M	–	460
2020 Q4	$19.9M	Sell	116,600 -1,800	-2%	-$267K	0.81%	35
2020 Q3	$16.6M	Sell	118,400 -23,200	-16%	-$3.53M	0.82%	33
2020 Q2	$22.7M	Buy	141,600 +18,100	+15%	+$2.46M	1.3%	25
2020 Q1	$12.1M	Buy	123,500 +4,250	+4%	+$486K	0.89%	33
2019 Q4	$15.4M	Buy	+119,250	New	+$12M	0.85%	30

Other funds holding SRPT

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

E. Ohman J:or Asset Management's SRPT Position: Q1 2021 in Review

E. Ohman J:or Asset Management sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 116,600 shares — an estimated $19.9M sold.

E. Ohman J:or Asset Management first reported a position in SRPT in Q4 2019 and held it in 5 quarters. The position peaked at $22.7M in Q2 2020. 367 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

E. Ohman J:or Asset Management reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
E. Ohman J:or Asset Management sold 116,600 Sarepta Therapeutics shares in Q1 2021, an estimated $19.9M.
E. Ohman J:or Asset Management first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 5 quarters.
E. Ohman J:or Asset Management's Sarepta Therapeutics position peaked at $22.7M in Q2 2020.
367 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on E. Ohman J:or Asset Management's 13F filing for Q1 2021, filed 5 Apr 2024.